L. Davies and H. G. Welch, “Current thyroid cancer trends in the United States,” JAMA Otolaryngol. - Head Neck Surg., 2014 Apr;140(4):317–22.
J. P. Brito, A. J. Yarur, L. J. Prokop, B. McIver, M. H. Murad, and V. M. Montori, “Prevalence of Thyroid Cancer in Multinodular Goiter Versus Single Nodule: A Systematic Review and Meta-Analysis,” Thyroid, 2013.
E. S. Cibas and S. Z. Ali, “The 2017 Bethesda System for Reporting Thyroid Cytopathology,” J. Am. Soc. Cytopathol., vol. 6, no. 6, pp. 217–222, 2017.
M. Bongiovanni, A. Spitale, W. C. Faquin, L. Mazzucchelli, and Z. W. Baloch, “The Bethesda system for reporting thyroid cytopathology: A meta-analysis,” Acta Cytologica. 2017;61(2):172.
R. L. Ferris, Z. Baloch, V. Bernet, et al “Risk stratification of the thyroid nodule with Bethesda indeterminate cytology, category III, IV, V on the one surgeon-performed US-guided fine-needle aspiration with 27-gauge needle, verified by histopathology of thyroidectomy: the additional value of on,” J. Am. Soc. Cytopathol., vol. 71, no. 6, pp. 131–136, 2018.
D. Ozdemir, N. Bestepe, S. Faki, A. Kilicarslan, O. Parlak, R. Ersoy, and B. Cakir, “Comparison of thyroid fine needle aspiration biopsy results before and after implementation of Bethesda classification,” Cytopathology, 2017 Oct;28(5):400–406.
P. S. Sullivan, S. L. Hirschowitz, P. C. Fung, and S. K. Apple, “The impact of atypia/follicular lesion of undetermined significance and repeat fine-needle aspiration: 5 years before and after implementation of the Bethesda System,” Cancer Cytopathol., 2014 Dec;122(12):866–72.
E. Machała, J. Sopiński, I. Iavorska, and K. Kołomecki, “Correlation of Fine Needle Aspiration Cytology of Thyroid Gland with Histopathological Results,” Polish J. Surg., vol. 90, no. 5, pp. 1–5, 2018.
H. Her-Juing Wu, C. Rose, and T. M. Elsheikh, “The Bethesda system for reporting thyroid cytopathology: An experience of 1,382 cases in a community practice setting with the implication for risk of neoplasm and risk of malignancy,” Diagn. Cytopathol., 2012 May;40(5):399–403.
F. F. R. Maia, P. S. Matos, E. J. Pavin, and D. E. Zantut-Wittmann, “Thyroid imaging reporting and data system score combined with Bethesda system for malignancy risk stratification in thyroid nodules with indeterminate results on cytology,” Clin. Endocrinol. (Oxf)., 2015 Mar;82(3):439–44.
J. D. Galbraith, N. Swann, B. Cox, N. Letendre, and J. Recabaren, “The bethesda classification for thyroid fine needle aspiration: A predictor or an alarmist?" in American Surgeon, 2018 Jan 1;84(1):161–164.
R. L. Ferris, Z. Baloch, V. Bernet, A. Chen, T. J. Fahey, I. Ganly, S. P. Hodak, E. Kebebew, K. N. Patel, A. Shaha, D. L. Steward, R. P. Tufano, S. M. Wiseman, and S. E. Carty, “American Thyroid Association Statement on Surgical Application of Molecular Profiling for Thyroid Nodules: Current Impact on Perioperative Decision Making,” Thyroid, vol. 25, no. 7, pp. 760–768, 2015.
H. Yodying, A. Matsuda, M. Miyashita, S. Matsumoto, N. Sakurazawa, M. Yamada, and E. Uchida, “Prognostic Significance of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Oncologic Outcomes of Esophageal Cancer: A Systematic Review and Meta-analysis,” Ann. Surg. Oncol., 2016 Feb;23(2):646–54.
H. Tang, W. Lu, B. Li, C. Li, Y. Xu, and J. Dong, “Prognostic significance of neutrophil-to-lymphocyte ratio in biliary tract cancers: a systematic review and meta-analysis,” Oncotarget, 2017 May 30;8(22):36857–36868.
Q. T. Huang, L. Zhou, W. J. Zeng, Q. Q. Ma, W. Wang, M. Zhong, and Y. H. Yu, “Prognostic significance of neutrophil-to-lymphocyte ratio in ovarian cancer: A systematic review and meta-analysis of observational studies,” Cellular Physiology and Biochemistry. 2017;41(6):2411–2418.
K. Atila, N. C. Arslan, S. Derici, A. E. Canda, O. Sagol, I. Oztop, and S. Bora, “Neutrophil-to-lymphocyte ratio: Could it be used in the clinic as prognostic marker for gastrointestinal stromal tumor?,” Hepatogastroenterology., vol. 61, no. 134, 2014.
C. Seretis, S. Gourgiotis, G. Gemenetzis, F. Seretis, E. Lagoudianakis, and G. Dimitrakopoulos, “The significance of neutrophil/lymphocyte ratio as a possible marker of underlying papillary microcarcinomas in thyroidal goiters: A pilot study,” Am. J. Surg., 2013 Jun;205(6):691–6.
J. Y. Kim, T. Park, S. H. Jeong, C. Y. Jeong, Y. T. Ju, Y. J. Lee, S. C. Hong, W. S. Ha, S. K. Choi, and E. J. Jung, “Prognostic importance of baseline neutrophil to lymphocyte ratio in patients with advanced papillary thyroid carcinomas,” Endocrine, 2014 Aug;46(3):526–31.
C. L. Liu, J. J. Lee, T. P. Liu, Y. C. Chang, Y. C. Hsu, and S. P. Cheng, “Blood neutrophil-to-lymphocyte ratio correlates with tumor size in patients with differentiated thyroid cancer,” J. Surg. Oncol., 2013 Apr;107(5):493–7.
B. H. H. Lang, C. P. C. Ng, K. B. Au, K. P. Wong, K. K. C. Wong, and K. Y. Wan, “Does preoperative neutrophil lymphocyte ratio predict risk of recurrence and occult central nodal metastasis in papillary thyroid carcinoma?,” World J. Surg., 2014 Oct;38(10):2605–12.
B. Haugen, E. K. Alexander, K. C. Bible, and et al, “2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer,” The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer, 2016 Jan;26(1):1–133.
F. Lee, P.-S. Yang, M.-N. Chien, J.-J. Lee, C.-H. Leung, and S.-P. Cheng, “An Increased Neutrophil-to-Lymphocyte Ratio Predicts Incomplete Response to Therapy in Differentiated Thyroid Cancer.,” Int. J. Med. Sci., 2018 vol. 15, no. 14, pp. 1757–1763.
D. Kocer, C. Karakukcu, H. Karaman, F. Gokay, and F. Bayram, “May the neutrophil/lymphocyte ratio be a predictor in the differentiation of different thyroid disorders?,” Asian Pacific J. Cancer Prev., vol. 16, no. 9, pp. 3875–3879, 2015.
N. Xu, Y. Jian, Y. Wang, and W. Tian, “Evaluation of neutrophil-to-lymphocyte ratio and calcitonin concentration for predicting lymph node metastasis and distant metastasis in patients with medullary thyroid cancer.,” Mol. Clin. Oncol., 2018v ol. 9, no. 6, pp. 629–634.
W. Gong, S. Yang, X. Yang, and F. Guo, “Blood preoperative neutrophil-to-lymphocyte ratio is correlated with TNM stage in patients with papillary thyroid cancer,” Clinics, vol. 71, no. 6, pp. 311–314, 2016.
S. Ozmen, O. Timur, I. Calik, K. Altinkaynak, E. Simsek, H. Gozcu, A. Arslan, and A. Carlioglu, “Neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) may be superior to C-reactive protein (CRP) for predicting the occurrence of differentiated thyroid cancer,” Endocr. Regul., vol. 51, no. 3, pp. 131–136, 2017.
J. F. Liu, L. Ba, H. Lv, D. Lv, J. T. Du, X. M. Jing, N. J. Yang, S. X. Wang, C. Li, and X. X. Li, “Association between neutrophil-to-lymphocyte ratio and differentiated thyroid cancer: A meta-analysis,” Sci. Rep. 2016, vol. 6, pp. 1–7.
D. K. Manatakis, S. Tseleni-Balafouta, D. Balalis, V. N. Soulou, D. P. Korkolis, G. H. Sakorafas, G. Plataniotis, and E. Gontikakis, “Association of Baseline Neutrophil-to-Lymphocyte Ratio with Clinicopathological Characteristics of Papillary Thyroid Carcinoma,” Int. J. Endocrinol., vol. 2017, 2017:8471235.
D. K. Manatakis, S. Tseleni-Balafouta, L. Tzelves, D. Balalis, A. Tzortzopoulou, D. P. Korkolis, G. H. Sakorafas, E. Gontikakis, and G. Plataniotis, “Diagnostic Accuracy of Preoperative Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Detecting Occult Papillary Thyroid Microcarcinomas in Benign Multinodular Goitres,” J. Thyroid Res., vol. 2018, pp. 1–6, 2018.